longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

FOSUN PHARMA

600196

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 17.16, below the reasonable range, cheaper than 98.53% of the time in the past 5 years, and the industry ranks 32/221, the industry Median 23.07.

17.16xP/E
¥21.78Stock price
¥1.27Earnings per share
17.16xP/E
Stock price¥21.78Earnings per share¥1.27

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
24.47x
Typical range
20.85x–29.99x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 23.07x
019385776

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 23.07x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
000538SZYunnan Baiyao
17.56x7.35%¥91.69B
600196SHFOSUN PHARMA
17.16x13.38%¥58.16B
688578SHAllist
16.54x31.69%¥44.29B
000999SZCR Sanjiu
12.11x3.34%¥39.67B
600079SHHWHG
14.81x28.07%¥30.07B
000423SZDEEJ
16.34x12.09%¥29.16B
002603SZYILING PHARMACEUTICAL
18.37x16.88%¥25.26B
000513SZLIVZON GROUP
13.91x4.33%¥23.30B
600566SHJUMPCAN
12.61x--¥23.18B
600535SHTASLY
17.03x20.77%¥20.83B
000623SZJI LIN AO DONG
6.54x--¥20.70B
002773SZKHPG
17.78x--¥17.74B
600380SHJoincare
13.99x9.59%¥16.76B
600062SHCR Double-Crane
10.17x7.36%¥16.41B
600867SHTHDB
11.79x47.85%¥15.32B
600750SHCRJZ
16.23x6.25%¥14.21B
605507SHGuobang Pharma
19.15x--¥13.53B
600267SHHISUN
15.30x39.13%¥13.43B
300573SZXingqi Pharmaceutical
16.27x--¥12.87B
600216SHZMC
14.96x19.78%¥12.06B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.